Rx Medicare

CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world’s leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.

Read More…

Related Posts

• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• Practice Fusion Identifies 300,000 High-Risk Patients For H1N1 Influenza Vaccine, In-line With CDC Pandemic Guidelines
• USDA Conducting Confirmatory Testing On Possible Detection Of 2009 Pandemic H1N1 Influenza In U.S. Swine
• Baxter Receives European Commission Approval For CELVAPAN H1N1 Pandemic Influenza Vaccine
• Baxter Receives EMEA Positive Opinion For CELVAPAN H1N1 Pandemic Influenza Vaccine
• European Medicines Agency Recommends Authorisation Of Two Vaccines For Influenza Pandemic (H1N1) 2009
• CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season
• Swine Flu: NIAID Set To Launch Clinical Trials To Test 2009 H1N1 Influenza Vaccine Candidates
• Diagnostic Hybrids Receives FDA Emergency Use Authorization For D3 Ultra 2009 H1N1 Influenza A Virus ID Kit
• VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine To Biological E.; Vaccine Could Become Available For Use In India This Year
• Statement By The Welsh Assembly Government On Latest Developments In Respect Of The Influenza A (H1N1) Swine Flu Pandemic
• H1N1 Health Alert: Children With Asthma At Greater Risk From H1N1 Influenza
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• Groups At High Risk Of H1N1 Influenza A Should Avoid Travelling To 2009 HAJJ
• Potential Allergen In H1N1 Swine Flu Vaccine May Put Children At Risk-Only Phadia Reveals Both Presence And Severity Of The Allergy

Tags: 2009, biotherapies, children, efficacy, free, h1n1, influenza, licensure, monovalent, obtains, pandemic, thimerosal, vaccine

This entry was posted on Tuesday, November 17th, 2009 at 1:11 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.